JP2553474B2 - Skin cosmetics - Google Patents

Skin cosmetics

Info

Publication number
JP2553474B2
JP2553474B2 JP24548188A JP24548188A JP2553474B2 JP 2553474 B2 JP2553474 B2 JP 2553474B2 JP 24548188 A JP24548188 A JP 24548188A JP 24548188 A JP24548188 A JP 24548188A JP 2553474 B2 JP2553474 B2 JP 2553474B2
Authority
JP
Japan
Prior art keywords
skin
effect
test
salt
molecular weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP24548188A
Other languages
Japanese (ja)
Other versions
JPH0296509A (en
Inventor
喬太郎 蓮沼
敬美 佐々木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kanebo Ltd
Original Assignee
Kanebo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanebo Ltd filed Critical Kanebo Ltd
Priority to JP24548188A priority Critical patent/JP2553474B2/en
Publication of JPH0296509A publication Critical patent/JPH0296509A/en
Application granted granted Critical
Publication of JP2553474B2 publication Critical patent/JP2553474B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/736Chitin; Chitosan; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)

Description

【発明の詳細な説明】 (技術分野) 本発明は、低分子量の酸性ムコ多糖類及びその塩と、
ホパンテン酸アルカリ金属塩の少なくとも一種とを併用
含有してなる皮膚老化防止効果(荒肌改善効果、角質改
善効果、角質層のターンオーバーを速くする効果、美肌
効果等)に優れた皮膚化粧料に関する。
TECHNICAL FIELD The present invention relates to a low molecular weight acidic mucopolysaccharide and a salt thereof,
A skin cosmetic excellent in the effect of preventing skin aging (rough skin improving effect, keratin improving effect, horny layer turnover accelerating effect, beautiful skin effect, etc.) containing at least one type of alkali metal hopanthenate in combination .

(従来技術) 老化皮膚とは乾燥して滑らかさのない荒れた肌で、角
質細胞の剥離現象が認められ、結合組織はコラーゲン/
エラスチン比が高く、しわが多い。また、老化皮膚は細
胞代謝の低下により角質層のターンオーバーが遅く、従
って皮膚に老化防止効果が付与発現するとターンオーバ
ーが速くなると言われ、種々の皮膚細胞賦活成分や血行
促進成分を配合した皮膚化粧料が提案されている。
(Prior Art) Aging skin is dry and rough skin that is exfoliated by keratinocytes and the connective tissue is collagen /
High elastin ratio and many wrinkles. It is said that in aging skin, the turnover of the stratum corneum is slow due to a decrease in cell metabolism, and therefore, the turnover becomes faster when the anti-aging effect is imparted to the skin. Cosmetics have been proposed.

しかし、従来より提案された皮膚化粧料のいずれも
が、例えば、しっとりした肌にする、滑らかな肌にする
等の皮膚表面の改質に資することは出来ても、積極的に
老化皮膚防止効果を期待する程に優れた皮膚化粧料を得
ることは困難であった。
However, although any of the conventionally proposed skin cosmetics can contribute to the modification of the skin surface, for example, to make the skin moist, smooth, etc., it has a positive effect on preventing aging skin. It was difficult to obtain an excellent skin cosmetic as expected.

皮膚老化防止効果を期待するためには、皮膚細胞賦活
作用又は血行促進作用を有する成分を皮膚化粧料に配合
することが、適当なる技術的条件であっても、それだけ
の技術的要素のみで、期待する程度の老化防止効果が発
現するものではない。
In order to expect the effect of preventing skin aging, it is necessary to blend a component having a skin cell activating action or a blood circulation promoting action into a skin cosmetic, even under appropriate technical conditions, with only such technical elements, It does not exhibit the expected anti-aging effect.

即ち、皮膚細胞は、真皮層に存在する皮膚毛細血管よ
り滲出してくる皮膚細胞賦活成分や皮膚細胞の栄養素を
取り込んで、正常な細胞代謝を営んでいる。
That is, the skin cells take in the skin cell activating components and the nutrients of the skin cells that are exuded from the skin capillaries existing in the dermis layer, and perform normal cell metabolism.

しかし、真皮層にあっては、その構成成分、特に構造
性糖蛋白と共に、線維性蛋白の間隙を埋めている酸性ム
コ多糖類、例えば、ヒアルロン酸、デルマタン硫酸、コ
ンドロイチン硫酸、ヘパラン硫酸等の成分から構成され
る真皮の基質成分、或いは表皮にあっては、基底細胞、
有棘細胞、顆粒細胞そして角質細胞の間隙を埋めている
リンパ液や脂質類及び酸性ムコ多糖類糖から構成されて
いる間充物質層を皮膚細胞賦活成分等が泳動し、真皮で
は線維芽細胞等、表皮では基底細胞や有棘細胞等に到達
し、該成分がそれぞれの細胞内に円滑に取り込まれて初
めて、期待せる老化防止効果が発現するのである。
However, in the dermis layer, along with its constituents, especially structural glycoproteins, acidic mucopolysaccharides that fill the interstices of fibrous proteins, such as hyaluronic acid, dermatan sulfate, chondroitin sulfate, heparan sulfate, and other components. Dermal matrix component composed of, or in the epidermis, basal cells,
Skin cell activating components migrate to the mesothelial material layer composed of lymph fluid, lipids and acidic mucopolysaccharide sugar filling the gaps between spiny cells, granule cells and keratinocytes, and fibroblasts etc. in the dermis. In the epidermis, the expected aging-preventing effect is exhibited only when the cells reach basal cells, spiny cells, etc., and the components are smoothly taken into each cell.

然るに、老化皮膚は、表皮細胞層が菲薄化していると
共に、表皮細胞中の基質及び間充物質を構成せる成分で
あるリンパ液や酸性ムコ多糖類等の成分の存在量が減少
し、そのため末梢血管から滲出してくる皮膚細胞賦活成
分や皮膚細胞の栄養素は基質成分層や間充物質層を充分
に泳動し得ず、そして細胞の該成分の取込みが充分に行
われず、従って老化防止効果が期待する程には発現しな
いのである。
However, in aging skin, the epidermal cell layer is thinned, and the amount of components such as lymph and acidic mucopolysaccharide, which are the components that make up the matrix and mesothelial substances in the epidermal cells, is reduced, and therefore peripheral blood vessels are reduced. Skin cell activating components and skin cell nutrients exuding from the skin cannot migrate sufficiently in the matrix component layer or the mesothelial substance layer, and the uptake of the components by the cells is not sufficiently carried out, and therefore anti-aging effect is expected. It does not appear to the extent that it does.

かかる皮膚毛細血管と皮膚細胞との間に介在する基質
成分や間充物質の構成を正常化して、皮膚細胞賦活成分
や皮膚細胞の栄養素等が皮膚細胞に円滑に取り込まれる
ような成分を配合してなる皮膚化粧料の提案は未だに皆
無である。
By normalizing the composition of matrix components and mesogens that are present between the skin capillaries and skin cells, the skin cell activating components and components such as skin cell nutrients are incorporated into the skin cells smoothly. There are still no proposals for skin cosmetics.

(発明の開示) 本発明者は、上述の問題点に鑑み研究した結果、特願
昭62-075448公報に記載の如く、「平均分子量が1000-10
0000である低分子量の酸性ムコ多糖類及びその塩の少な
くとも一種と、ホパンテン酸カルシウムとを配合したこ
とを特徴とせる皮膚化粧料」なる発明を完成した。
(Disclosure of the Invention) As a result of research in view of the above-mentioned problems, the present inventor has found that, as described in Japanese Patent Application No. 62-075448, "the average molecular weight is 1000-10
The present invention has been completed as "a skin cosmetic characterized by containing at least one low-molecular weight acidic mucopolysaccharide having a molecular weight of 0000 and a salt thereof, and calcium fopanthenate."

しかし、本発明の目的とする皮膚老化防止効果に優れ
た皮膚化粧料に関して、更に、鋭意研究した結果、後記
特定の低分子量の酸性ムコ多糖類及びその塩の少なくと
も一種と、ホパンテン酸アルカリ金属塩の少なくとも一
種とを併用含有した皮膚化粧料は、先の特願昭62-07544
8号に記載の発明に係わる皮膚化粧料と比較して、皮膚
老化防止効果に一段と優れ、保存安定性、角質層のター
ンオーバーを速める効果、荒肌改善効果、及び角質改善
効果に著効を呈すると共に皮膚に湿潤性(しっとり
感)、柔軟性(滑らか感)、弾力性(張り)及び艶を付
与し得る美肌効果をも発現することを見出し本発明を完
成するに至った。
However, as for the skin cosmetics excellent in the effect of preventing skin aging, which is the object of the present invention, as a result of further intensive studies, at least one of the specific low-molecular weight acidic mucopolysaccharides and salts thereof described later and an alkali metal fopanthenate salt. The skin cosmetics containing at least one of the
Compared with the skin cosmetics according to the invention described in No. 8, it is much more excellent in the effect of preventing skin aging, storage stability, the effect of accelerating turnover of the stratum corneum, the effect of improving rough skin, and the effect of improving keratin. The present invention has been completed by discovering that it exhibits a moisturizing effect (moist feeling), flexibility (smooth feeling), elasticity (tension), and a beautiful skin effect capable of imparting luster to the skin.

(発明の目的) 即ち、本発明の目的は、保存安定性並びに荒肌改善効
果、改質改善効果、角質層のターンオーバーを速める効
果、美肌効果等の皮膚老化防止効果に優れた皮膚化粧料
を提供することにある。
(Object of the Invention) That is, the object of the present invention is a skin cosmetic excellent in storage stability and rough skin improving effect, reforming improving effect, effect of accelerating turnover of the stratum corneum, and skin aging preventing effect such as beautiful skin effect. To provide.

(発明の構成) 本発明は、平均分子量が1000-100000である低分子量
の酸性ムコ多糖類及びその塩の少なくとも一種と、ホパ
ンテン酸アルカリ金属塩の少なくとも一種とを含有した
ことを特徴とした皮膚化粧料である。
(Structure of the Invention) The present invention is characterized by containing at least one kind of low molecular weight acidic mucopolysaccharide having an average molecular weight of 1,000 to 100,000 and a salt thereof, and at least one kind of alkali metal fopanthenate. Cosmetics.

(発明の具体的な説明) 本発明に用いる酸性ムコ多糖類、即ちヒアルロン酸、
デルマタン硫酸、コンドロイチン硫酸、ヘパラン硫酸等
は公知の物質であって、軟骨、関節、眼球、皮膚その他
の結合組織に基質成分となって、蛋白質と結合して動物
体内に広く分布している。
(Detailed Description of the Invention) The acidic mucopolysaccharide used in the present invention, namely hyaluronic acid,
Dermatan sulfate, chondroitin sulfate, heparan sulfate and the like are known substances, and are widely distributed in the animal body by forming a matrix component in cartilage, joints, eyes, skin and other connective tissues, binding to proteins.

本発明に用いる低分子量の酸性ムコ多糖類及びその塩
は、下記の如くして得ることができる。
The low molecular weight acidic mucopolysaccharides and salts thereof used in the present invention can be obtained as follows.

(1)低分子ヒアルロン酸及びその塩 平均分子量が100万の市販されているヒアルロン酸5g
を、100mlの0.02Nの塩酸水溶液に分散溶解し、pH=2〜
3に調製して充分に撹拌しつつ温浴中で65℃に加温し
た。この加温処理時間を各々10分から120分に変えるこ
とにより、平均分子量が1千から10万のヒアルロン酸を
得ることができる。
(1) Low molecular weight hyaluronic acid and its salt 5 g of commercially available hyaluronic acid with an average molecular weight of 1 million
Is dispersed and dissolved in 100 ml of 0.02N hydrochloric acid aqueous solution, and the pH is 2 to 2.
The mixture was adjusted to 3 and heated to 65 ° C. in a warm bath with sufficient stirring. By changing the heating treatment time from 10 minutes to 120 minutes, hyaluronic acid having an average molecular weight of 1,000 to 100,000 can be obtained.

次いで、1N−苛性ソーダで中和した後、該溶液を室温
まで冷却し、エタノール3倍容を加えて得られる沈殿物
をエタノールで洗浄した後、乾かして低分子量ヒアルロ
ン酸ナトリウム塩の粉末を得た。また、この低分子量ヒ
アルロン酸ナトリウム塩を酸で処理して遊離のヒアルロ
ン酸とし、次にこれを他の塩基性物質で処理して、例え
ば、カリウム塩、トリエタノールアミノ塩、L−アルギ
ニン塩等の塩類を調製した。
Then, after neutralizing with 1N-caustic soda, the solution was cooled to room temperature, and a precipitate obtained by adding 3 volumes of ethanol was washed with ethanol and dried to obtain low-molecular weight hyaluronic acid sodium salt powder. . In addition, this low molecular weight hyaluronic acid sodium salt is treated with an acid to give free hyaluronic acid, which is then treated with another basic substance, for example, potassium salt, triethanolamino salt, L-arginine salt, etc. Was prepared.

(2)低分子量コンドロイチン硫酸及びその塩等 平均分子量が5万の市販されているコンドロイチン硫
酸ナトリウム5gを50mlの水に溶かし、アンバーライトIR
-120(H型)のレジンカラムに通して得られる流出液を
充分に撹拌しつつ、温浴中で75℃に加温した。この加温
処理時間を各々10分から120分に変えることにより、平
均分子量が1000〜100000のコンドロイチン硫酸を得るこ
とができる。次いで、1N−苛性ソーダで中和する。該溶
液を室温まで冷却後、エタノール3倍容を加えて得られ
る沈殿物を遠心分離し、エタノールで洗滌した後、乾燥
してコンドロイチン硫酸ナトリウム塩の粉末を得た。次
いで、このコンドロイチン硫酸ナトリウム塩を酸で処理
して遊離のコンドロイチン硫酸とし、次にこれを他の塩
基性物質で処理して、例えば、カリウム塩、トリエタノ
ールアミン塩、L−アルギニン塩等の塩類を調製した。
(2) Low molecular weight chondroitin sulfate and its salts, etc. 5 g of commercially available sodium chondroitin sulfate having an average molecular weight of 50,000 was dissolved in 50 ml of water, and Amberlite IR was used.
The effluent obtained by passing through a -120 (H type) resin column was heated to 75 ° C in a warm bath while being sufficiently stirred. By changing the heating treatment time from 10 minutes to 120 minutes, chondroitin sulfate having an average molecular weight of 1,000 to 100,000 can be obtained. It is then neutralized with 1N-caustic soda. After the solution was cooled to room temperature, 3 times volume of ethanol was added, the resulting precipitate was centrifuged, washed with ethanol, and dried to obtain a powder of chondroitin sulfate sodium salt. Then, this sodium chondroitin sulfate salt is treated with an acid to give free chondroitin sulfate, and then this is treated with another basic substance, for example, a salt such as a potassium salt, a triethanolamine salt or an L-arginine salt. Was prepared.

また、低分子量デルマタン硫酸、低分子量ヘパラン硫
酸等についても、上記コンドロイチン硫酸の例と同様の
処理により、遊離状或いはそれぞれの塩類を調製した。
Also, low molecular weight dermatan sulfate, low molecular weight heparan sulfate, etc. were prepared in free form or their respective salts by the same treatment as in the above example of chondroitin sulfate.

尚、各処理時間により得られた酸性ムコ多糖類の平均
分子量の測定方法は、ソモギー−ネルソン(Somogyi-Ne
lson)法を用いた。
The method for measuring the average molecular weight of the acidic mucopolysaccharide obtained by each treatment time was Somogyi-Nelson (Somogyi-Ne
lson) method was used.

ホパンテン酸アルカリ金属塩は、例えばホパンテン酸
のナトリウム塩、カリウム塩、リチウム塩であるが公知
の物質である。
The alkali metal hopanthenic acid is a known substance, for example, sodium salt, potassium salt, and lithium salt of hopanthenic acid.

また、ホパンテン酸カルシウムと同様に、通常の製法
にて得ることができる。
Moreover, it can be obtained by an ordinary production method in the same manner as calcium fopanthenate.

本発明の皮膚化粧料に用いるホパンテン酸アルカリ金
属塩類は、上述のホパンテン酸カルシウムと比べ皮膚化
粧料中の保存安定性ならびに老化皮膚のターンオーバー
を速める効果、荒肌改善効果、角質改善効果等の全てに
優れ、持続的な血行促進作用が皮膚細胞を賦活して優れ
た皮膚老化防止効果を発現し、更には、皮膚細胞の代謝
機能を正常化して、美肌効果を高めるものと推察され
る。
The alkali metal salts of hopanthenic acid used in the skin cosmetics of the present invention have effects such as storage stability in skin cosmetics and the effect of accelerating turnover of aged skin, rough skin improving effect, and keratin improving effect as compared with the above-mentioned calcium hopantenate. It is presumed that all of them are excellent and have a continuous blood circulation stimulating effect to activate skin cells to exert an excellent anti-aging effect on skin, and further normalize the metabolic function of skin cells to enhance the skin beautiful effect.

ホパンテン酸アルカリ金属塩の配合量は、本発明の皮
膚化粧料の組成物の全重量に対して0.05〜2.0重量%
(以下wt%と略記する)であればよく、好ましくは0.1
〜1.5wt%である。配合量が0.05wt%未満では、本発明
の目的とする効果が充分でなく、一方2.0wt%を超えて
も、その増加分に見合った効果の向上は望めないもので
ある。
The compounding amount of the alkali metal hopanthenate is 0.05 to 2.0% by weight based on the total weight of the composition of the skin cosmetic of the present invention.
(Hereinafter abbreviated as wt%), preferably 0.1
~ 1.5wt%. If the blending amount is less than 0.05 wt%, the effect aimed at by the present invention is not sufficient. On the other hand, if it exceeds 2.0 wt%, improvement in the effect commensurate with the increase cannot be expected.

また、本発明者は、皮膚化粧料中に含有する上記構成
物質の相乗効果を最大限に発揮させる含有割合に関し
て、種々探究した結果、(1)低分子量の酸性ムコ多糖
類及びその塩、(2)ホパンテン酸アルカリ金属塩のそ
れぞれの含有量の比率(重量比)は(1):(2)=1:
0.01〜1:1である場合が好ましく、本発明の目的とする
優れた効果が認められた。
In addition, the present inventor conducted various researches on the content ratio of the above-mentioned constituents contained in the skin cosmetic composition to maximize the synergistic effect, and as a result, (1) low-molecular-weight acidic mucopolysaccharides and salts thereof, ( 2) The ratio (weight ratio) of the respective contents of the alkali metal hopanthenate is (1) :( 2) = 1:
It is preferably 0.01 to 1: 1 and the excellent effect aimed at by the present invention was observed.

即ち、この(2)の血行促進剤が皮膚細胞に隣接する
真皮内の末梢毛細血管の血行を促進し、血液中に含まれ
ている皮膚細胞賦活成分と皮膚細胞の栄養素の真皮組織
内への滲出を活発にし、更に、(1)が皮膚細胞を取り
囲む基質成分の構成比を改善することにより、皮膚細胞
の皮膚細胞賦活成分等の物質の取り込みを円滑に行うな
わしめ、皮膚細胞の新陳代謝を促進するとともに、
(1)の優れた抱水能力が皮膚に適度な水の付与と保留
に貢献し、美肌効果をも発現せしめるという効果を奏し
得たのである。
That is, the blood circulation accelerating agent of (2) promotes blood circulation in peripheral capillaries in the dermis adjacent to skin cells, and the skin cell activating components and skin cell nutrients contained in the blood are transferred to the dermis tissue. By stimulating the exudation and further improving the composition ratio of the substrate component that surrounds the skin cells in (1), the smooth absorption of substances such as the skin cell activation component of the skin cells is promoted, and the metabolism of the skin cells is improved. Along with promoting
The excellent water-holding ability of (1) contributed to the appropriate application and retention of water to the skin, and the effect of exhibiting a beautiful skin effect could be achieved.

また、低分子量酸性ムコ多糖類及びその塩の配合量
は、化粧料組成物の全重量に対して、0.01〜2.0wt%あ
ればよく、各々の配合量の下限未満では、本発明が目的
とする効果に充分でなく、一方、上限を越えても、その
増加分に見合った効果の向上は望めないものである。
Further, the blending amount of the low molecular weight acidic mucopolysaccharide and the salt thereof may be 0.01 to 2.0 wt% with respect to the total weight of the cosmetic composition. However, even if the upper limit is exceeded, it is not possible to expect an improvement in the effect commensurate with the increase.

本発明の皮膚化粧料には、上記の他に各種油剤、多価
アルコール、紫外線吸収剤、色素、香料、防腐剤、界面
活性剤、顔料、抗酸化剤、増粘剤、樹脂模形成剤等を本
発明の目的を達成する範囲内で適宜配合することができ
る。
In addition to the above, the skin cosmetics of the present invention include various oils, polyhydric alcohols, ultraviolet absorbers, dyes, fragrances, preservatives, surfactants, pigments, antioxidants, thickeners, resin-forming agents, etc. Can be appropriately blended within a range that achieves the object of the present invention.

また、本発明の皮膚化粧料の剤型は、スキンローショ
ン類、乳液類、クリーム類、パック類、ファンデーショ
ン類など任意に調製することができる。
Further, the dosage form of the skin cosmetic of the present invention can be arbitrarily prepared such as skin lotions, emulsions, creams, packs and foundations.

(実施例) 以下、実施例及び比較例に基づいて本発明を詳細に説
明する。
(Example) Hereinafter, the present invention will be described in detail based on Examples and Comparative Examples.

尚、化粧料中の保存安定性試験、荒肌改善効果試験、
角質改善効果試験、角質層のターンオーバー測定試験、
官能テスト(美肌効果試験)は下記の通りである。
In addition, storage stability test in cosmetics, rough skin improvement effect test,
Horny layer improvement effect test, stratum corneum turnover measurement test,
The sensory test (Beautiful skin effect test) is as follows.

(1)保存安定性試験 45℃と5℃の恒温室に3ヶ月間保存した後、ローショ
ン類(後述)では肉眼判定による外観の濁り、また、乳
化物類(後述)では同じく分離状態を観察し評価した。
良好なものを……○、不良なものを……×として表し
た。
(1) Storage stability test After storage in a temperature-controlled room at 45 ° C and 5 ° C for 3 months, the lotion (described later) has a visually opaque appearance and the emulsions (described later) also shows a separated state. And evaluated.
Good ones are indicated as ◯ ○, and bad ones are indicated as ×.

(2)荒肌改善効果試験 下脚に荒れ肌を有する中高年被験者20名を対象として
4週間連続塗布効果を調べた。被験者の左側下脚試験部
位に1日1回約1gの試料を塗布し、試験開始前及び終了
後の皮膚の状態を下記の判定基準により判定した。右側
下脚は試料を塗布せず対照とした。
(2) Rough skin improvement effect test 20 middle-aged and elderly subjects having rough skin on the lower legs were tested for the application effect for 4 consecutive weeks. About 1 g of the sample was applied to the left lower leg test site of the test subject once a day, and the condition of the skin before and after the start of the test was evaluated according to the following criteria. The lower right leg was not coated with the sample and served as a control.

皮膚乾燥度の判定基準 − :正常 ± :軽微乾燥、落屑なし + :乾燥、落屑軽度 ++ :乾燥、落屑中等度 +++:乾燥、落屑顕著 試験前後の試験部位と対照部位の判定結果を比較し、
皮膚乾燥度が2段階以上改善された場合(例えば、+→
−、++→±)を有効、1段階改善された場合をやや有
効、変化がなかった場合を無効とした。試験結果は有
効、やや有効となった被験者の人数で示した。
Criteria for skin dryness −: Normal ±: Minor dryness, no desquamation +: Dry, mild desquamation ++: Dry, moderate desquamation +++: Dryness, remarkable desquamation Compare the determination results of the test site before and after the test and the control site,
When the skin dryness is improved by two or more steps (for example, + →
−, ++ → ±) is valid, 1 is slightly improved when it is improved, and is invalid when there is no change. The test results were shown by the number of subjects who were valid or slightly valid.

(3)角質改善(角質細胞の抗剥離性増大)効果試験 前述の荒肌改善効果試験開始前及び終了後の被験者皮
膚にスコッチテープ(ニチバンメンディングテープ)を
接着し、これを剥離した時テープに付着した角質細胞の
状態を走査型電子顕微鏡によって詳細に調べ、下記の基
準によって皮膚角質細胞抗剥離性を解析し、角質改善効
果を求めた。
(3) Keratin improvement (increased anti-peeling property of keratinocytes) effect test Scotch tape (Nichiban Mending Tape) was adhered to the subject's skin before and after the rough skin improvement effect test described above, and the tape was peeled off. The state of the keratinocytes adhered to was examined in detail by a scanning electron microscope, and the skin keratinocyte anti-exfoliation property was analyzed according to the following criteria to determine the keratin improving effect.

角質改善効果(角質細胞抗剥離性増大)の判定基準 評価点1:スケールを認めず 2:小スケール点在 3:小〜中スケール顕著 4:大スケール顕著 評価は4週間連続塗布後の試験部位の評価点と対照部
位のそれとの差が2点以上の場合を有効、1点の場合を
やや有効、0点の場合を無効とした。判定結果は有効、
やや有効となった被験者の人数で示した。
Criteria for keratin improvement effect (increased keratinocyte anti-exfoliation) Evaluation point 1: No scale is observed 2: Small scale is scattered 3: Small to medium scale is remarkable 4: Large scale is remarkable Evaluation is a test site after 4 weeks continuous application When the difference between the evaluation points of 1 and 2 was 2 points or more, it was judged as valid, 1 point as slightly valid, and 0 point as invalid. Judgment result is valid,
It is shown by the number of subjects who were slightly effective.

(4)角質層のターンオーバー測定試験 蛍光色素のダンシルクロライドを白色ワセリン中に5
重量%配合した軟膏を作り、被験者20名の前腕部の皮膚
に24時間閉塞貼付し、角質層にダンシルクロライドを浸
透結合させる。その後同じ部位に1日2回(朝・夕)試
験試料を塗布し、毎日ダンシルクロライドの蛍光を調
べ、その蛍光が消滅するまでの日数を皮膚角質層のター
ンオーバーとした。
(4) Turnover measurement test of the stratum corneum The fluorescent dye dansyl chloride was added to white petrolatum 5 times.
Make an ointment containing 20% by weight and apply it to the skin of the forearm of 20 test subjects for 24 hours, and dansyl chloride is permeated and bonded to the stratum corneum. After that, the test sample was applied to the same site twice a day (morning and evening), the fluorescence of dansyl chloride was examined every day, and the number of days until the fluorescence disappeared was defined as the turnover of the stratum corneum of the skin.

判定結果は被験者の日数の平均値で示した。尚、通常
の皮膚角質層のターンオーバーは14〜16日であるが、老
化した皮膚においては18日前後にのびる。それに対して
老化防止効果が現れると12日前後にまで短縮される。
The judgment results are shown as the average number of days of the subjects. The normal turnover of the stratum corneum is 14 to 16 days, but in aged skin it extends around 18 days. On the other hand, when the anti-aging effect appears, it is shortened to around 12 days.

(5)官能テスト(美肌効果試験) 荒れ肌、小皺、乾燥肌等を訴える女子被験者(35〜55
才)20人に試料を1日2回(朝・夕)連続3ヶ月後の効
果を評価した。試験結果は、皮膚の湿潤性、平滑性、弾
力性の各項目に対して、皮膚に潤いが生じた、皮膚が滑
らかになった、皮膚に張りが生じたと回答した人数で示
した。
(5) Sensory test (Beautiful skin effect test) Female subjects who complain of rough skin, fine wrinkles, dry skin (35-55)
20 years old, the effect of the sample was evaluated twice a day (morning and evening) after 3 consecutive months. The test results were expressed by the number of people who answered that the skin was moistened, the skin became smooth, and the skin became taut for each item of skin wettability, smoothness, and elasticity.

比較例1〜3、実施例1〜5 〔二層型スキンローション〕 下記の組成の如く、二層型スキンローション基剤にホ
パンテン酸アルカリ金属塩を第1表に記載の通りに配合
して各々のスキンローションを調製し、前記諸試験を実
施した。
Comparative Examples 1 to 3 and Examples 1 to 5 [Two-layer type skin lotion] As shown in Table 1, two-layer type skin lotion bases were mixed with alkali metal hopanthenate as shown in Table 1, respectively. The skin lotion was prepared and the above-mentioned tests were carried out.

尚、本発明に用いる酸性ムコ多糖類として、ヒアルロ
ン酸にHAと略記し、以下、ヒアルロン酸ナトリウム(HA
-N)、コンドロイチン硫酸(CO)、コンドロイチン硫酸
トリエタノールアミン(CO-T)、コンドロイチン硫酸L
−アルギニン(CO-A)、デルマタン硫酸(DE)、デルマ
タン硫酸カリウム(DE-K)、ヘパラン硫酸(HP)、ヘパ
ラン硫酸ナトリウム(HP-N)と略記する。
In addition, as an acidic mucopolysaccharide used in the present invention, hyaluronic acid is abbreviated as HA, and hereinafter, sodium hyaluronate (HA
-N), chondroitin sulfate (CO), chondroitin sulfate triethanolamine (CO-T), chondroitin sulfate L
-Abbreviated as arginine (CO-A), dermatan sulfate (DE), potassium dermatan sulfate (DE-K), heparan sulfate (HP), sodium heparan sulfate (HP-N).

(1)組成 (2)調製法 (C)成分のホパンテン酸アルカリ金属塩等及び
(D)成分の酸性ムコ多糖類を予め(B)成分中に混合
溶解し、(A)、(B)成分を各々均一に溶解した後、
(A)成分と(B)成分を混合撹拌分散し、次いで容器
に充填する。使用時には内容物を均一に振盪分散して使
用する。
(1) Composition (2) Preparation method (C) Component alkali metal salt of fopanthenic acid, etc. and (D) component acidic mucopolysaccharide are mixed and dissolved in the (B) component in advance, and the (A) and (B) components are uniformly mixed. After melting
The component (A) and the component (B) are mixed and dispersed by stirring, and then filled in a container. At the time of use, the contents should be evenly dispersed by shaking.

(3)特性 各二層型スキンローションの諸試験を実施した結果を
第1表右欄に記載した。
(3) Properties The results of various tests of each two-layer type skin lotion are shown in the right column of Table 1.

比較例1−3の酸性ムコ多糖類とホパンテン酸カルシ
ウムを配合した皮膚化粧料と比べて実施例1−5の本発
明の皮膚化粧料は諸試験の全てにおいて良好なる結果が
認められた。
In all the tests, the skin cosmetics of the present invention of Examples 1-5 showed favorable results in comparison with the skin cosmetics of Comparative Example 1-3 containing the acidic mucopolysaccharide and calcium hopanthenate.

尚、比較例1〜3は保存安定性試験に於いて、下層水
相部分の外観に濁りが生じた。
In addition, in Comparative Examples 1 to 3, in the storage stability test, the appearance of the lower aqueous phase portion became cloudy.

比較例4、実施例6−9 〔スキンクリーム〕 実施例1と同様に、下記の組成にて各々のスキンクリ
ームを調製し、諸試験を実施した結果を第2表右欄に示
した。
Comparative Example 4 and Examples 6-9 [Skin Cream] Similar to Example 1, each skin cream was prepared with the following composition and various tests were carried out. The results are shown in the right column of Table 2.

(1)組成 (2)調製法 (C)成分のホパンテン酸アルカリ金属塩等及び
(D)成分の酸性ムコ多糖類は(B)成分中に配合し
て、(A),(B)成分を各々80℃に加熱溶解した後、
混合して撹拌しつつ30℃まで冷却して各スキンクリーム
を調製した。
(1) Composition (2) Preparation method The alkali metal salt of fopanthenic acid as the component (C) and the acidic mucopolysaccharide as the component (D) are mixed in the component (B), and the components (A) and (B) are heated to 80 ° C, respectively. After melting by heating,
Each skin cream was prepared by mixing and stirring and cooling to 30 ° C.

(3)特性 第2表に示す如く、本発明の皮膚化粧料である実施例
6〜9のスキンクリームは、比較例4と比較して諸特性
の全てに亙って優れていることは明らかであり、配合特
性に於いても異常は認められなかった。
(3) Characteristics As shown in Table 2, it is clear that the skin creams of Examples 6 to 9 which are the skin cosmetics of the present invention are superior to Comparative Example 4 in all of their characteristics. No abnormality was found in the compounding characteristics.

尚、比較例4は保存安定性試験に於いて外観が分離状
態となった。
In Comparative Example 4, the appearance was separated in the storage stability test.

(発明の効果) 以上記載の如く、本発明の皮膚化粧料は、皮膚機能を
亢進し、皮膚の老化防止に顕著な効果を発現する優れた
皮膚化粧料を提供することが明らかである。
(Effect of the Invention) As described above, it is apparent that the skin cosmetic of the present invention provides an excellent skin cosmetic that enhances the skin function and exerts a remarkable effect in preventing skin aging.

Claims (1)

(57)【特許請求の範囲】(57) [Claims] 【請求項1】平均分子量が1000〜100000である低分子量
の酸性ムコ多糖類及びその塩の少なくとも一種と、ホパ
ンテン酸アルカリ金属塩の少なくとも一種とを含有した
ことを特徴とする皮膚化粧料。
1. A skin cosmetic comprising at least one low-molecular-weight acidic mucopolysaccharide having an average molecular weight of 1,000 to 100,000 and a salt thereof, and at least one alkali metal fopanthenic acid salt.
JP24548188A 1988-09-29 1988-09-29 Skin cosmetics Expired - Lifetime JP2553474B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP24548188A JP2553474B2 (en) 1988-09-29 1988-09-29 Skin cosmetics

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP24548188A JP2553474B2 (en) 1988-09-29 1988-09-29 Skin cosmetics

Publications (2)

Publication Number Publication Date
JPH0296509A JPH0296509A (en) 1990-04-09
JP2553474B2 true JP2553474B2 (en) 1996-11-13

Family

ID=17134301

Family Applications (1)

Application Number Title Priority Date Filing Date
JP24548188A Expired - Lifetime JP2553474B2 (en) 1988-09-29 1988-09-29 Skin cosmetics

Country Status (1)

Country Link
JP (1) JP2553474B2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3308433B2 (en) * 1995-08-31 2002-07-29 株式会社資生堂 Skin activating food
JP3687277B2 (en) * 1997-06-10 2005-08-24 サンスター株式会社 Whitening cosmetics
US20080300389A1 (en) * 2007-06-04 2008-12-04 Yang David J Metal-polysaccharide conjugates: compositions, synthesis and methods for cancer therapy

Also Published As

Publication number Publication date
JPH0296509A (en) 1990-04-09

Similar Documents

Publication Publication Date Title
KR20180123036A (en) Composition for moisturizing and use thereof
WO1999024009A1 (en) Uses of d-xylose, the esters thereof and oligosaccharides containing xylose for improving the functionality of epidermal cells
CN109350591B (en) Dry facial mask for beautifying face and preparation method thereof
JPH0465047B2 (en)
JPH06104620B2 (en) Skin cosmetics
JP2553474B2 (en) Skin cosmetics
JPH0733637A (en) Skin cosmetic
JP2511817B2 (en) Skin cosmetics
JP2511820B2 (en) Skin cosmetics
JP2611956B2 (en) Skin cosmetics
JPH0696514B2 (en) Skin cosmetics
JPS63150210A (en) Hair-tonic cosmetic
JP2559678B2 (en) Hair nourishing cosmetics
JP2004075635A (en) Moisturizing agent and external preparation for skin
JPH08104607A (en) Cosmetic
JP3534934B2 (en) Skin cosmetics
JPS63159304A (en) Skin cosmetic
JPS63139104A (en) Skin cosmetic
KR960012607B1 (en) Cosmetic composition for dryness prevention of skin
JPS62153206A (en) Skin cosmetic
JPS62249912A (en) Skin cosmetic
JPS6366109A (en) Skin cosmetic
JPH062661B2 (en) Skin cosmetics
JPS6377809A (en) Skin cosmetic
JPH0692290B2 (en) Skin cosmetics